4 Healthcare Stock Stories for a Midweek Investment Checkup

Sanofi-Aventis (NYSE:SNY): Closing price $47.94

On Wednesday, Sanofi US and POZEN Inc. reported the signing of an exclusive license arrangement for the commercialization of POZEN’s proprietary, investigational, coordinated-delivery tablets uniting immediate-release omeprazole, a proton pump inhibitor, and enteric-coated  aspirin in a single tablet, PA8140 and  PA32540.

Through the terms, Sanofi will hold exclusive rights to commercialize all PA combinations which contain 325 g or less of enteric-coated aspirin in the United States. POZEN will obtain an upfront payment of $15 million and become eligible for pre-commercial milestone payments of as much as $20 million, along with other future milestone payments and royalties on product sales.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY-20130904

Endo Health Solutions Inc. (NASDAQ:ENDP): Closing price $43.06

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions and BioDelivery Sciences International, Inc. said Wednesday that they have finalized interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine. The interim analyses were run as part of the Phase III protocol to allow for adjustments to the sample size so as to maintain appropriate study power to identify statistically significant differences between BEMA Buprenorphine and placebo. The analyses were conducted by an independent biostatistician.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ENDP-20130904

Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP): Closing price $3.09

Chelsea reported Wednesday that the FDA has acknowledged the receipt of the new drug application resubmission requesting approval to market Northera (droxidopa) — which is an orally active synthetic precursor of norepinephrine — for the treatment of symptomatic neurogenic orthostatic hypotension. The resubmission includes additional information to settle certain technical deficiencies previously noted by the Agency.

The FDA considers the current resubmission a complete response to its March 28, 2012 complete response letter and assigned a new Prescription Drug User Fee Act goal date of February 14,

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

2014.CHTP-20130904

Myriad Genetics, Inc. (NASDAQ:MYGN): Closing price $27.25

Myriad announced today that it has reached an expanded, nonexclusive world collaboration accord with AstraZeneca, through which to provide companion diagnostics for the olaparib Phase 3 clinical development program. Olaparib is an investigational orally active poly-ADP ribose polymerase inhibitor being developed by AstraZeneca for the treatment of several tumor types that include BRCA-mutated breast and ovarian cancers. Through the expanded arrangement, Myriad will build out a new laboratory within its Salt Lake City facility working with FDA regulations for companion diagnostic devices.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYGN-20130904

Don’t Miss: Glaxo Hasn’t Escaped China Bribery Charges Quite Yet.